< Terug naar vorige pagina


Relationship between glycaemic variability and hyperglycaemic clamp-derived functional variables in (impending) type 1 diabetes

Tijdschriftbijdrage - Tijdschriftartikel

AIMS/HYPOTHESIS: We examined whether measures of glycaemic variability (GV), assessed by continuous glucose monitoring (CGM) and self-monitoring of blood glucose (SMBG), can complement or replace measures of beta cell function and insulin action in detecting the progression of preclinical disease to type 1 diabetes.

METHODS: Twenty-two autoantibody-positive (autoAb(+)) first-degree relatives (FDRs) of patients with type 1 diabetes who were themselves at high 5-year risk (50%) for type 1 diabetes underwent CGM, a hyperglycaemic clamp test and OGTT, and were followed for up to 31 months. Clamp variables were used to estimate beta cell function (first-phase [AUC5-10 min] and second-phase [AUC120-150 min] C-peptide release) combined with insulin resistance (glucose disposal rate; M 120-150 min). Age-matched healthy volunteers (nā€‰=ā€‰20) and individuals with recent-onset type 1 diabetes (nā€‰=ā€‰9) served as control groups.

RESULTS: In autoAb(+) FDRs, M 120-150 min below the 10th percentile (P10) of controls achieved 86% diagnostic efficiency in discriminating between normoglycaemic FDRs and individuals with (impending) dysglycaemia. M 120-150 min outperformed AUC5-10 min and AUC120-150 min C-peptide below P10 of controls, which were only 59-68% effective. Among GV variables, CGM above the reference range was better at detecting (impending) dysglycaemia than elevated SMBG (77-82% vs 73% efficiency). Combined CGM measures were equally efficient as M 120-150 min (86%). Daytime GV variables were inversely correlated with clamp variables, and more strongly with M 120-150 min than with AUC5-10 min or AUC120-150 min C-peptide.

CONCLUSIONS/INTERPRETATION: CGM-derived GV and the glucose disposal rate, reflecting both insulin secretion and action, outperformed SMBG and first- or second-phase AUC C-peptide in identifying FDRs with (impending) dysglycaemia or diabetes. Our results indicate the feasibility of developing minimally invasive CGM-based criteria for close metabolic monitoring and as outcome measures in trials.

Tijdschrift: Diabetologia
ISSN: 0012-186X
Issue: 12
Volume: 58
Pagina's: 2753-2764
Jaar van publicatie:2015
  • DOI: https://doi.org/10.1007/s00125-015-3761-y
  • Scopus Id: 84946495091
  • WoS Id: 000364221200009
  • ORCID: /0000-0002-9007-5203/work/58116995
  • ORCID: /0000-0002-9007-6177/work/60767443
  • ORCID: /0000-0002-8671-4527/work/61349279
  • ORCID: /0000-0002-6440-2485/work/61423350
  • ORCID: /0000-0003-2304-5298/work/61726057
  • ORCID: /0000-0001-7179-1717/work/83057854